Sign in

You're signed outSign in or to get full access.

AT

Allogene Therapeutics, Inc. (ALLO)·Q3 2025 Earnings Summary

Executive Summary

  • EPS beat on disciplined OpEx: Q3 2025 GAAP EPS was ($0.19) vs S&P Global consensus of ($0.23), driven by sequential and YoY reductions in R&D and G&A; no impairment this quarter versus prior-year Q3 aided comparability . EPS consensus from S&P Global data*.
  • Cash runway maintained into 2H 2027; quarter-end cash, cash equivalents and investments were $277.1M; 2025 cash burn ~$150M and GAAP OpEx ~$230M reiterated .
  • Clinical execution stable: ALPHA3 (cema-cel) remains on track for MRD-based futility analysis in 1H 2026; 50+ sites active with international expansion to Australia/South Korea expected early 2026; central MRD testing by Foresight to standardize readouts .
  • Pipeline catalysts: ASH TIP poster on ALPHA3 (Dec 7); initial biomarker/PoC data from ALLO-329 in autoimmune disease targeted for 1H 2026; ALLO-316 program continuing toward next-phase planning following RCC responses .

What Went Well and What Went Wrong

  • What Went Well

    • Cost discipline: R&D fell to $31.2M (vs $40.2M in Q2 and $44.7M YoY); G&A to $13.7M (vs $14.3M in Q2 and $16.3M YoY), helping drive the EPS beat .
    • Clinical momentum: >50 ALPHA3 sites active across US/Canada; futility analysis focused on MRD conversion remains on track for 1H 2026; international site activations planned early 2026 .
    • Management tone/confidence: “We are creating [the future of cell therapy] with conviction, with data, and with a platform built for lasting impact,” positioning Allogene XL as scalable and economically viable, per CEO remarks .

  • What Went Wrong

    • Prior safety headwind: August regimen shift removed ALLO-647 following a grade 5 event attributed to ALLO-647 in the FCA arm; the trial now proceeds with standard FC only .
    • Enrollment pacing complexities: Q1 commentary cited site readiness delays and milestone timing shifts to 1H 2026; management has since streamlined design and centralized MRD, but the timeline still reflects the earlier reset .
    • No revenue contribution: The company remains pre-revenue, limiting fundamental P&L levers beyond OpEx control; “Revenues” not reported in the quarter, consistent with prior updates .

Financial Results

  • P&L summary and balance sheet (chronological: oldest → newest)
MetricQ3 2024Q1 2025Q2 2025Q3 2025
R&D Expense ($M)$44.7 $50.2 $40.2 $31.2
G&A Expense ($M)$16.3 $15.0 $14.3 $13.7
Impairment ($M)$10.7 — $2.4 —
Total OpEx ($M)$71.8 $65.2 $56.8 $44.9
Net Loss ($M)$(66.3) $(59.7) $(50.9) $(41.4)
GAAP EPS$(0.32) $(0.28) $(0.23) $(0.19)
Wt Avg Shares (M)209.2 215.4 218.9 222.0
Cash & Investments ($M)—$335.5 $302.6 $277.1
Total Assets ($M)—$508.0 $470.6 $439.8
Total Liabilities ($M)—$122.6 $126.0 $124.4
Stockholders’ Equity ($M)—$385.4 $344.6 $315.3
  • Results vs estimates
MetricQ3 2025 ActualQ3 2025 ConsensusSurprise
GAAP EPS$(0.19) $(0.23)*+$0.04 (beat)
RevenueN/A (pre-revenue) $1.82M*N/M

Values with asterisks are retrieved from S&P Global.

  • KPIs (program execution)
    • ALPHA3 sites active: >50 sites across US/Canada; Australia/South Korea expected to open early 2026 .
    • ALPHA3 futility: MRD-conversion-focused futility analysis planned for 1H 2026; MRD tested centrally by Foresight Diagnostics .
    • Autoimmune (ALLO-329): Phase 1 RESOLUTION enrolling; first biomarker/PoC readout planned 1H 2026 .

Segment breakdown: Not applicable (clinical-stage, no product revenue) .

Guidance Changes

MetricPeriodPrevious Guidance (as of Q2 2025)Current Guidance (Q3 2025)Change
Cash Burn (Δ Cash, Cash Equivalents & Investments)FY 2025~$150M decrease ~$150M decrease Maintained
GAAP Operating ExpensesFY 2025~ $230M (incl. ~$45M SBC) ~ $230M (incl. ~$45M SBC) Maintained
Cash RunwayMulti-yearInto 2H 2027 Into 2H 2027 Maintained

No revenue, margin, OI&E, tax rate, dividend guidance provided .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1–Q2 2025)Current Period (Q3 2025)Trend
ALPHA3 futility/MRDFutility & LD selection shifted to 1H26 due to site readiness; 250+ consents for MRD; >50 sites activated MRD-based futility remains on track for 1H26; >50 sites active; international additions in early 2026; 30% MRD conversion “bar” framed as meaningful Stable execution; narrative sharpened on MRD bar
LD regimenMoved to standard FC; FCA arm closed after ALLO-647-related grade 5 AE Reinforced standard FC approach; investigators favor standard CAR-T regimen; slight uptick in screening pace Cleaner regimen supports enrollment
Autoimmune (ALLO-329)Trial initiation planned mid-2025; PoC moved to 1H26 to include biomarkers + clinical data Phase 1 enrolling; dual CD19/CD70 with Dagger aims to reduce/avoid LD; 1H26 biomarker/PoC targeted Progressing as guided
Solid tumor (ALLO-316)RCC Phase 1b data at ASCO; aligned with FDA on pivotal trial design Durable responses in RCC reiterated; next-phase planning ongoing Preparing for potential advancement/partnering
RegulatoryAligned with FDA for ALLO-316 design Ongoing, timely FAA interactions; single-time CAR-T path “wide open”; CMC scrutiny acknowledged Constructive dialogue
Manufacturing/platformCost realignment extends runway; preserving core mfg capabilities Allogene XL positioned as scalable, efficient backbone; lower cost of care thesis emphasized Platform narrative strengthened
SafetyFCA arm closed after ALLO-647 AE No new severe viral infection cases under FC; central MRD standardization Risk mitigated, ops streamlined

Management Commentary

  • CEO strategic framing: “We are advancing the platform… to make the promise of curative one-time off-the-shelf cell therapy a reality today… Allogene XL Technology delivers the scalable backbone needed to democratize access, reduce the overall cost of care” .
  • CMO on MRD bar/context: Achieving ~30% delta in MRD conversion vs observation “would represent the largest improvement in lymphoma outcomes since the approval of rituximab,” citing POLARIX (7% PFS delta) and the analogous InVIGOR-11 data .
  • CFO on financial posture: “Cash runway… extends into the second half of 2027… 2025 cash burn of approximately $150 million; full-year GAAP operating expenses of approximately $230 million” .

Q&A Highlights

  • Futility readout scope and bar: Company will focus on MRD conversion only at futility (no alpha spending); 30% MRD-conversion delta framed as a strong outcome; enrollment on track with slight screening uptick post-FC-only regimen .
  • Site readiness: Of the 50+ sites, nearly all are now open to enrollment; central MRD testing at Foresight ensures consistency .
  • Autoimmune program expectations: Initial 1H 2026 update to include biomarker + early clinical responses in a “handful” of patients; cohorts include reduced LD (cyclophosphamide) and no LD, leveraging Dagger .
  • Regulatory tone: Ongoing, timely FDA interactions; single-time CAR-T path remains viable; CMC rigor anticipated .

Estimates Context

  • Q3 2025 EPS: Actual ($0.19) vs S&P Global consensus ($0.23)*; beat by $0.04, aided by lower R&D/G&A and no impairment vs prior-year comp .
  • Revenue: Company did not report revenue this quarter; S&P Global consensus modeled ~$1.82M*, which is not meaningful given the pre-revenue stage .
  • Street models may reduce outer-year OpEx assumptions modestly given multi-quarter OpEx trend lower and reaffirmed FY OpEx guide; focus likely shifts to clinical probability-of-success (ALPHA3 MRD conversion) rather than near-term P&L .

Values with asterisks are retrieved from S&P Global.

Key Takeaways for Investors

  • EPS beat was quality-driven by sustained OpEx discipline; trend suggests FY OpEx guidance is achievable without compromising key clinical milestones .
  • The pivotal ALPHA3 futility analysis in 1H 2026 is the major stock catalyst; management’s 30% MRD-conversion “bar” anchors expectations and, if achieved, could be practice-changing .
  • Safety risk tied to ALLO-647 has been removed; standard FC regimen appears to support investigator comfort and may aid screening/enrollment .
  • The centralized MRD assay (Foresight) reduces variability risk—important for a futility decision tied to MRD conversion .
  • Autoimmune read-in (ALLO-329) 1H 2026 could broaden the story beyond oncology, with potential to demonstrate efficacy without LD—an adoption and tolerability advantage if validated .
  • Cash runway into 2H 2027 provides funding through both 1H 2026 catalysts; any upside from partnerships (e.g., ALLO-316) could further de-risk capital needs .
  • Near-term trading setup: ASH TIP poster on ALPHA3 (Dec 7) keeps attention on design/assay strategy; the primary re-rating awaits futility data and autoimmune PoC in 1H 2026 .
Notes
- All S&P Global estimate values are denoted with an asterisk (*) and sourced from S&P Global consensus.